Female Contraception (Women's and Male Health) - Drugs in Development, 2021

December 2021 | 128 pages | ID: F73724677E55EN
Global Markets Direct

Abstracts

Female Contraception (Women's and Male Health) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception – Drugs In Development, 2021, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization, and natural methods. Contraception generally works by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 3, 2, 6, 4, 1, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 2 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
• The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Female Contraception - Drug Profiles
Female Contraception - Dormant Projects
Female Contraception - Discontinued Products
Female Contraception - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Female Contraception, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Female Contraception - Pipeline by Adare Pharma Solutions, 2021
Female Contraception - Pipeline by Agile Therapeutics Inc, 2021
Female Contraception - Pipeline by Cirqle Biomedical Contraception IVS, 2021
Female Contraception - Pipeline by Dare Bioscience Inc, 2021
Female Contraception - Pipeline by Evestra Inc, 2021
Female Contraception - Pipeline by Evofem Biosciences Inc, 2021
Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, 2021
Female Contraception - Pipeline by Hervana Ltd, 2021
Female Contraception - Pipeline by Insud Pharma, 2021
Female Contraception - Pipeline by Luye Pharma Group Ltd, 2021
Female Contraception - Pipeline by Lyndra Therapeutics Inc., 2021
Female Contraception - Pipeline by MedinCell SA, 2021
Female Contraception - Pipeline by Micron Biomedical Inc, 2021
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, 2021
Female Contraception - Pipeline by Mucommune LLC, 2021
Female Contraception - Pipeline by Myovant Sciences Ltd, 2021
Female Contraception - Pipeline by Navad Life Sciences Pte Ltd, 2021
Female Contraception - Pipeline by Noven Pharmaceuticals Inc, 2021
Female Contraception - Pipeline by Ohana BioSciences Inc, 2021
Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, 2021
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Female Contraception - Pipeline by Viramal Ltd, 2021
Female Contraception - Pipeline by Yaso Therapeutics Inc, 2021
Female Contraception - Pipeline by YourChoice Therapeutics Inc, 2021
Female Contraception - Pipeline by ZabBio Inc, 2021
Female Contraception - Dormant Projects, 2021
Female Contraception - Dormant Projects, 2021 (Contd..1)
Female Contraception - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Female Contraception, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021